A Phase 4 interventional study of Esomeprazole and Esomeprazole in Non Erosive Reflux Disease and Chronic Gastritis, sponsored by AstraZeneca. Completed at 8 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2012-09-28.
Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To compare the symptom control rate between 8 weeks esomeprazole treatment regimen group and 2 weeks esomeprazole treatment regimen group in co-diagnosed NERD and chronic gastritis patients, as evaluated by GerdQ after 24 weeks maintenance treatment/follow up.
A multicenter, randomized, open-label Phase IV study exploring symptom control rate in co-diagnosed NERD and chronic gastritis patients treated with 8 weeks esomeprazole treatment regimen and 2 weeks esomeprazole treatment regimen.
47 studies on the registry are indexed under Non-Erosive Reflux Disease; 8 are open to participants now.
This study's enrollment of 305 is above the median of 160 across 34 interventional studies indexed under Non-Erosive Reflux Disease.
Browse Non-Erosive Reflux Disease studies →AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
20 mg q.d. (quaque die) once a day dosing for 8 weeks
Drug: Esomeprazole
20 mg q.d. (quaque die) once a day dosing for 2 weeks
Drug: Esomeprazole
20mg Esomeprazole once daily, 8 weeks and 24 weeks on-demand treatment
20mg Esomeprazole once daily, 2 weeks and 24 weeks follow up
Symptom Control Rate at 24 Weeks Assessed by Gerd Q Questionnaire.
GerdQ Scores ranging from 0 to 3 were applied for the positive predictors and from 3 to 0 (reversed order, where 3 = none) for negative predictors. The GerdQ score was calculated as the sum of these scores, giving a total score ranging from 0 to 18. When GerdQ ≥8, the patients could be symptom based diagnosed as GERD. GerdQ was consisted of 3 categories: A, B and C. Each category has two questions with sum of score ranging from 0 to 6. Symptom controlled was defined as patients with all items ≤1 in A and C category of GerdQ.
Time frame: 24 weeks
The Success Rate in Whole Study Duration.
Success is defined as patients with symptom relief after 8 weeks or 2 weeks esomeprazole treatment, and also get symptom controlled during maintenance treatment / follow-up period.
Time frame: 24 weeks after end of treatment
Time to First Relapse.
Time to first relapse is from the last dose during the treatment period to date of first time patient comes to the investigator due to symptom recure and need for treatment. Time to first relapse is actually the time when 50% of patients had relapse. Up to the end of study, there were less than 50% of the patients in arm esomeprazole 2 weeks group had relapse so was unable to compute this endpoint
Time frame: From baseline to 24 weeks after end of treatment
Symptom Relief Rate in 2 Treatment Regimens.
Symptom relief is defined as no more than 1 day of mild symptoms of GERD during previous 7 days after 8 weeks or 2 weeks of treatment.
Time frame: 8 weeks for arm 1, 2 weeks for arm 2
Symptom Relief Rate After 2 Weeks and 8 Weeks in 8 Weeks Treatment Group.
Symptom relief is defined as no more than 1 day of mild symptoms of GERD during previous 7 days after 8 weeks or 2 weeks of treatment.
Time frame: 2 and 8 weeks
Number of Patients With Unscheduled Hospital Visit(s)
Time frame: from baseline to week 24 after end of treatment
Percentage of Patients Satisfaction
Satisfied - satisfaction score of 1-4 while very satisfied - satisfaction score of 1-2.
Time frame: 24 weeks after end of treatment
Symptom Control Rate at 8 Weeks Assessed by Gerd Q Questionnaire
GerdQ Scores ranging from 0 to 3 were applied for the positive predictors and from 3 to 0 (reversed order, where 3 = none) for negative predictors. The GerdQ score was calculated as the sum of these scores, giving a total score ranging from 0 to 18. When GerdQ ≥8, the patients could be symptom based diagnosed as GERD. GerdQ was consisted of 3 categories: A, B and C. Each category has two questions with sum of score ranging from 0 to 6. Symptom controlled was defined as patients with all items ≤1 in A and C category of GerdQ.
Time frame: 8 weeks
Symptom Control Rate at 16 Weeks Assessed by Gerd Q Questionnaire
GerdQ Scores ranging from 0 to 3 were applied for the positive predictors and from 3 to 0 (reversed order, where 3 = none) for negative predictors. The GerdQ score was calculated as the sum of these scores, giving a total score ranging from 0 to 18. When GerdQ ≥8, the patients could be symptom based diagnosed as GERD. GerdQ was consisted of 3 categories: A, B and C. Each category has two questions with sum of score ranging from 0 to 6. Symptom controlled was defined as patients with all items ≤1 in A and C category of GerdQ.
Time frame: 16 weeks
Three hundred and five patients, out of the 311 patients who signed the informed consent, were randomized to receive 8 weeks (n=154) or 2 weeks (n=151) of esomeprazole treatment.
| Milestone | Esomeprazole 8 Weeks Treatment | Esomeprazole 2 Weeks Treatment |
|---|---|---|
| Started | 154 | 151 |
| Completed | 136 | 126 |
| Not completed | 18 | 25 |
| Withdrew: Lack of efficacy | 18 | 25 |
| Milestone | Esomeprazole 8 Weeks Treatment | Esomeprazole 2 Weeks Treatment |
|---|---|---|
| Started | 136 | 124 |
| Completed | 135 | 122 |
| Not completed | 1 | 2 |
GerdQ Scores ranging from 0 to 3 were applied for the positive predictors and from 3 to 0 (reversed order, where 3 = none) for negative predictors. The GerdQ score was calculated as the sum of these scores, giving a total score ranging from 0 to 18. When GerdQ ≥8, the patients could be symptom based diagnosed as GERD. GerdQ was consisted of 3 categories: A, B and C. Each category has two questions with sum of score ranging from 0 to 6. Symptom controlled was defined as patients with all items ≤1 in A and C category of GerdQ.
| percentage of participants | Esomeprazole 8 Weeks Treatment | Esomeprazole 2 Weeks Treatment |
|---|---|---|
| Symptom Control Rate at 24 Weeks Assessed by Gerd Q Questionnaire. | 94.9 | 87.3 |
Success is defined as patients with symptom relief after 8 weeks or 2 weeks esomeprazole treatment, and also get symptom controlled during maintenance treatment / follow-up period.
| percentage of participants | Esomeprazole 8 Weeks Treatment | Esomeprazole 2 Weeks Treatment |
|---|---|---|
| The Success Rate in Whole Study Duration. | 83.8 | 72.8 |
Time to first relapse is from the last dose during the treatment period to date of first time patient comes to the investigator due to symptom recure and need for treatment. Time to first relapse is actually the time when 50% of patients had relapse. Up to the end of study, there were less than 50% of the patients in arm esomeprazole 2 weeks group had relapse so was unable to compute this endpoint
| days | Esomeprazole 8 Weeks Treatment | Esomeprazole 2 Weeks Treatment |
|---|---|---|
| Time to First Relapse. | NA (35 to NA) | 57 (12 to 174) |
Symptom relief is defined as no more than 1 day of mild symptoms of GERD during previous 7 days after 8 weeks or 2 weeks of treatment.
| percentage of participans | Esomeprazole 8 Weeks Treatment | Esomeprazole 2 Weeks Treatment |
|---|---|---|
| Symptom Relief Rate in 2 Treatment Regimens. | 88.3 | 83.4 |
Symptom relief is defined as no more than 1 day of mild symptoms of GERD during previous 7 days after 8 weeks or 2 weeks of treatment.
| percentage of participants | Esomeprazole 8 Weeks Treatment | Esomeprazole 2 Weeks Treatment |
|---|---|---|
| 2 weeks | 54.5 | — |
| 8 weeks | 88.3 | — |
| participants | Esomeprazole 8 Weeks Treatment | Esomeprazole 2 Weeks Treatment |
|---|---|---|
| Number of Patients With Unscheduled Hospital Visit(s) | 59 | 80 |
Satisfied - satisfaction score of 1-4 while very satisfied - satisfaction score of 1-2.
| percentage of participants | Esomeprazole 8 Weeks Treatment | Esomeprazole 2 Weeks Treatment |
|---|---|---|
| Satisfied | 100 | 96 |
| Very satisfied | 48.5 | 24.6 |
GerdQ Scores ranging from 0 to 3 were applied for the positive predictors and from 3 to 0 (reversed order, where 3 = none) for negative predictors. The GerdQ score was calculated as the sum of these scores, giving a total score ranging from 0 to 18. When GerdQ ≥8, the patients could be symptom based diagnosed as GERD. GerdQ was consisted of 3 categories: A, B and C. Each category has two questions with sum of score ranging from 0 to 6. Symptom controlled was defined as patients with all items ≤1 in A and C category of GerdQ.
| percentage of participants | Esomeprazole 8 Weeks Treatment | Esomeprazole 2 Weeks Treatment |
|---|---|---|
| Symptom Control Rate at 8 Weeks Assessed by Gerd Q Questionnaire | 80.1 | 75.4 |
GerdQ Scores ranging from 0 to 3 were applied for the positive predictors and from 3 to 0 (reversed order, where 3 = none) for negative predictors. The GerdQ score was calculated as the sum of these scores, giving a total score ranging from 0 to 18. When GerdQ ≥8, the patients could be symptom based diagnosed as GERD. GerdQ was consisted of 3 categories: A, B and C. Each category has two questions with sum of score ranging from 0 to 6. Symptom controlled was defined as patients with all items ≤1 in A and C category of GerdQ.
| percentage of participants | Esomeprazole 8 Weeks Treatment | Esomeprazole 2 Weeks Treatment |
|---|---|---|
| Symptom Control Rate at 16 Weeks Assessed by Gerd Q Questionnaire | 85.3 | 80.2 |
Collected over From baseline to 24 weeks after treatment.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Esomeprazole 8 Weeks Treatment | — | 0/154 (0%) | 0/154 (0%) |
| Esomeprazole 2 Weeks Treatment | — | 0/151 (0%) | 0/151 (0%) |
| Age, Categorical(Participants) | Esomeprazole 8 Weeks Treatment | Esomeprazole 2 Weeks Treatment | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 143 | 140 | 283 |
| >=65 years | 11 | 11 | 22 |
| Age Continuous(years) | Esomeprazole 8 Weeks Treatment | Esomeprazole 2 Weeks Treatment | Total |
|---|---|---|---|
| Mean | 45.9 ± 12.72 | 44.9 ± 13.12 | 45.4 ± 12.91 |
| Sex: Female, Male(Participants) | Esomeprazole 8 Weeks Treatment | Esomeprazole 2 Weeks Treatment | Total |
|---|---|---|---|
| Female | 80 | 54 | 134 |
| Male | 74 | 97 | 171 |
| Region of Enrollment(participants) | Esomeprazole 8 Weeks Treatment | Esomeprazole 2 Weeks Treatment | Total |
|---|---|---|---|
| China | 154 | 151 | 305 |
The record gives a start of Apr 2010, a primary completion of Jun 2011 and a completion of Jun 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2012, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Esomeprazole